These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M Respiration; 2014; 88(3):199-207. PubMed ID: 25115833 [TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787 [TBL] [Abstract][Full Text] [Related]
30. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750 [TBL] [Abstract][Full Text] [Related]
33. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis. Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995 [TBL] [Abstract][Full Text] [Related]
34. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Hagmeyer L; Treml M; Priegnitz C; Randerath WJ Respiration; 2016; 91(4):327-32. PubMed ID: 27073887 [TBL] [Abstract][Full Text] [Related]
35. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study. Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933 [TBL] [Abstract][Full Text] [Related]
36. Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone? Hosein K; Le J; Mura M Lung; 2017 Feb; 195(1):101-105. PubMed ID: 27858160 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Yoon HY; Kim DS; Song JW Respiration; 2019; 97(3):242-251. PubMed ID: 30332670 [TBL] [Abstract][Full Text] [Related]
38. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Xaubet A; Serrano-Mollar A; Ancochea J Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635 [TBL] [Abstract][Full Text] [Related]
39. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Vancheri C; Sebastiani A; Tomassetti S; Pesci A; Rogliani P; Tavanti L; Luppi F; Harari S; Rottoli P; Ghirardini A; Kirchgaessler KU; Albera C Respir Med; 2019 Sep; 156():78-84. PubMed ID: 31445389 [TBL] [Abstract][Full Text] [Related]
40. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]